Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (3): 6-11.doi: 10.6040/j.issn.1671-7554.0.2018.074
CHONG Tie, CHEN Qi
CLC Number:
| [1] 那彦群, 叶章群, 孙颖浩, 等. 2014年版《膀胱过度活动症诊断与治疗指南》[M]. 北京: 人民卫生出版社, 2014: 330-335. [2] Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China[J]. Neurourol Urodyn, 2011, 30(8): 1448-1455. [3] Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses[J]. Eur Urol, 2012, 62(6): 1040-1060. [4] DSouza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended—release and immediate release overactive bladder medications in a regional managed care plan[J]. J Manag Care Pharm, 2008, 14(3): 291-301. [5] Benner JS, Nichol MB, Rovener ES, et al. Patient-reported reasons for discontinuing overactive bladder of medication[J]. BJU Int, 2010, 105(9): 1276-1282. [6] Takasu T, Ukai M, Sato S, et al. Effect of(R)-2-(2-aminothiazol-4-yl)-4’-{2-[(-hydroxy-2-phenylethyl)amino] ethyl} acetanilide(YM178), a novel selective beta 3-adrenoceptor agonist, on bladder function[J]. J Pharmacol Exp Ther, 2007, 321(2):642-647. [7] Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder[J]. Neurourol Urology, 2007, 26(6): 752-756. [8] Ouslander JG. Management of overactive bladder[J]. N Engl J Med, 2004, 350(8): 786-799. [9] Michel MC, Cernecka H, Ochodnicky P. Desirable properties of β3-adrenoceptor agonists: implication for the selection of drug development candidates[J]. Eur J Pharamacol, 2011, 657(1-3): 1-3. [10] Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction[J]. BJU Int, 2012, 110(2b): E132-E142. [11] Andersson KE, Arner A. Urinary bladder contraction and relaxation drelaxation: physiology and pathophysinology[J]. Physiol Rev, 2001, 84(3): 935-986. [12] Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium[J]. Naunys Schmiedebergs Arch Pharmacol, 2008, 377(4-6): 473-481. [13] Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence[J]. Eur Urol, 2011, 59(3): 387-400. [14] Abrams P, Andersson K, Buccafusco J, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder[J]. Br J Pharmacol, 2006, 148(5): 565-578. [15] Irwin D, Mungapen L, Milsom L, et al. The economic impact of overactive bladder syndrome in six Western countries[J]. BJU Int, 2009, 103(2): 202-209. [16] Thiagamoorthy G, Kotes S, Zacchè M, et al. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder[J]. Ther Adv Urol, 2016, 8(1): 38-46. [17] Limberg B, Andersson K, Aura KF, et al. β-Adrenergic receptor subtype expression in myocyte and nonmyocyte cells in human female bladder[J]. Cell Tissue Res, 2010, 342(2): 295-306. [18] 李海源, 周逢海, 马玉磊, 等. 膀胱过度活动症治疗新药米拉贝隆[J]. 中国新药杂志, 2014, 23(19): 2215-2218. LI Haiyuan, ZHOU Fenghai, MA Yulei, et al. Mirabegron: a novel drug for overactive bladder symptom[J]. Chinese Journal of New Drugs, 2014, 23(19): 2215-2218. [19] Balachandran A. The efficacy and tolerability of mirabegron in a non-trial clinical setting[J]. Eur J Obstet Gynecol Reprod Biol, 2016, 200: 63-67. doi: 10.1016/j.ejogrb.2016.02.030. [20] Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK Clinical Practice[J]. Eur Urol, 2017, 72(3): 389-399. [21] Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from arandomised, double-blind, dose-ranging, phase 2 study(Symphony)[J]. Eur Urol, 2015, 67(3): 577-588. [22] Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial[J]. Eur Urol, 2013, 63(2): 283-295. [23] Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder[J]. J Urol, 2013, 189(4): 1388-1395. [24] Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder[J]. Urology, 2013, 82(2): 313-320. [25] Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia[J]. Neurourol Urodyn, 2015, 34(7): 685-692. [26] Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder[J]. Eur Urol, 2013, 63(2): 296-305. [27] Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome[J]. Eur Urol, 2016, 69(2): 311-323. [28] Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics[J]. Curr Med Res Opin, 2016, 32(4): 621-638. [29] Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome[J]. Eur Urol, 2005, 47(3): 376-384. [30] Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience[J]. BJU Int, 2012, 110(11): 1767-1774. [31] Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada[J]. Can Urol Assoc J, 2015, 9(9-10): 343-350. [32] Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects[J]. BJU Int, 2005, 95(3):335-340. [33] Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial[J]. BMC Urol, 2013, 13(18):45-52. |
| [1] | MA Xiang, ZHAO Feiyan. Status and progress of oocyte cryopreservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 19-23. |
| [2] | Chuanxin WANG. Liquid biopsy of tumor [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 64-71. |
| [3] | SHI Benkang. Advances in the diagnosis and treatment of overactive bladder [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 1-5. |
|
||
